Zhitong Finance App News, Harbin Pharmaceutical Co., Ltd. (600664.SH) issued an announcement. Recently, Harbin Pharmaceutical Group Bioengineering Co., Ltd., a subsidiary of the company, received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” on sodium sulfate issued by the State Drug Administration.

Sodium sulfate is one of the raw materials for oral administration of a concentrated solution of magnesium, sodium, and potassium sulfate. It exerts its medicinal effect through an osmotic laxative mechanism. A notice of approval for the marketing application for chemical raw materials was obtained this time, and its registration status changed to “A”, indicating that the API has met the relevant national drug evaluation technical standards. Subsequently, it is mainly used for the declaration and production of concentrated solutions for oral administration of the company-related formulation of magnesium, sodium, and potassium sulfate.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.